1. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations.
- Author
-
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, and Zisook S
- Subjects
- Aripiprazole administration & dosage, Bupropion administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Time Factors, Antidepressive Agents administration & dosage, Antipsychotic Agents administration & dosage, Depressive Disorder, Major drug therapy, Drug Substitution, Remission Induction methods, Research Design
- Abstract
Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant, we designed a trial of three "next-step" strategies: switching to another antidepressant (bupropion-SR) or augmenting the current antidepressant with either another antidepressant (bupropion-SR) or with an atypical antipsychotic (aripiprazole). The study will compare 12-week remission rates and, among those who have at least a partial response, relapse rates for up to 6 months of additional treatment. We review seven key efficacy/effectiveness design decisions in this mixed "efficacy-effectiveness" trial., (Copyright © 2015. Published by Elsevier Ireland Ltd.)
- Published
- 2015
- Full Text
- View/download PDF